Results 231 to 240 of about 843,559 (297)
The monoclonal antibody VYD2311 potently neutralizes dominant and emerging SARS-CoV-2 variants. [PDF]
Mellis IA +5 more
europepmc +1 more source
ABSTRACT Background Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell surface antigen 2 (TROP2)–directed antibody–drug conjugate (ADC) with a topoisomerase I inhibitor payload and was approved by the Japan Pharmaceuticals and Medical Devices Agency in 2025 for patients with unresectable or recurrent hormone receptor–positive (HR+)/human epidermal
Hiroko Shimada +18 more
wiley +1 more source
Preclinical evaluation of SLC35D3-targeted CAR-T cells for tumor-selective immunotherapy. [PDF]
Someya S +5 more
europepmc +1 more source
Abstract Objectives Viral infections are predominantly managed with conventional antiviral drugs, which, despite their efficacy, can cause toxicity and promote resistance. Cell‐based immunotherapies offer an alternative, but cytomegaloviruses (CMV) profoundly interfere with MHC class I antigen presentation, thereby impairing conventional virus‐specific
Sabrina Kübel +14 more
wiley +1 more source
Type-II-CD20-targeted therapy for CD38 antibody-refractory antibody-mediated rejection after kidney transplantation: a case report. [PDF]
de Fallois J +10 more
europepmc +1 more source
Plant Molecular Farming for Cancer Immunotherapy: Production, Glycoengineering, and Structural Insights into Therapeutic Monoclonal Antibodies. [PDF]
Tamayo-Ordoñez MC +15 more
europepmc +1 more source
Management of Bullous Pemphigoid and Norwegian Scabies with Dupilumab Plus Ivermectin. [PDF]
Zhang Y, Liu Y, Yi H.
europepmc +1 more source

